Page 4 - Phasei Study News Today

“We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed every year with TNBC,” says CEO and MD.

“We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed every year with TNBC,” says CEO and MD.

Presentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting Webinar on Monday, December 13th, at 9:00 a.m. ET BUFFALO,...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine

“It’s a proud moment to see CF33-hNIS-antiPDL1 (CHECKvacc) continue its progression and have this Phase I trial underway with patients at...

Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC populationOral presentation by Dr. Tanguy Y. Seiwert with comprehensive review of local and systemic potential effects of NBTXR3...

Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC population

Imugene collaborator wins FDA Investigational New Drug approval to initiate CHECKvacc phase one trial Imugene managing director and chief executive officer Leslie Chong called the approval a “major milestone” for the company as it prepares to commence a phase one trial into metastatic, triple-negative breast cancer with its CHECKvacc drug candidate. Imugene is a step closer to trialling its oncolytic virotherapy candidate in a phase one study on patients with triple-negative bre...

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders Objective response was observed in 60% of anti-PD-1 naïve patients and 50% of prior non-responders Data suggest abscopal effect in some patient...